Pharmacoeconomics

Papers
(The TQCC of Pharmacoeconomics is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods516
The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies192
Introduction to the Special Issue of PharmacoEconomics on Major Depressive Disorders82
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)78
The Burden of Type 2 Diabetes on the Productivity and Economy in Sub-Saharan Africa: A Life Table Modelling Analysis from a South African Perspective75
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children70
A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data58
A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies50
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision45
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment41
Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia38
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer35
Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review35
A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper34
Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values33
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework31
Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study30
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions30
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review25
Correction: Comparing the Psychometric Performance of Generic Paediatric Health‑Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression25
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature25
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review25
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?25
A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist24
Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Mo24
Unravelling Elements of Value of Healthcare and Assessing their Importance Using Evidence from Two Discrete-Choice Experiments in England23
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling22
Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study22
Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States22
Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience21
A Comparison of Methods for Identifying Informal Carers: Self-Declaration Versus a Time Diary21
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”21
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal21
Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches21
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis21
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment20
Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA20
Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights20
Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)20
A Value Set for the EQ-5D-Y-3L in the Netherlands18
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review18
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective18
Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries17
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?17
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment16
How Much Better is Faster? Value Adjustments for Health-Improvement Sequences16
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort16
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal16
Authors’ Response to “Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery”16
Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model16
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe15
Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening15
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals15
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments14
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy14
An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia14
Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation14
The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions14
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers13
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment13
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force13
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease13
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review12
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective12
Productivity Loss Across Socioeconomic Groups Among Patients With Low Back Pain or Osteoarthritis: Estimates Using the Friction-Cost Approach in Norway12
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?12
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers12
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy12
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review11
Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary11
Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies11
Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology11
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan11
Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer11
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation11
Acknowledgement to Referees11
Advancing Methods to Measure and Reward Healthcare Innovation11
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting11
Acknowledgement to Referees11
Acknowledgement to Referees11
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review11
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review10
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment10
Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresect10
Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma10
Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study10
Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies10
Making Composite Time Trade-Off Sensitive for Worse-than-Dead Health States10
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)10
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrin10
Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe Obesity9
Correction to: Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain9
Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial9
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy9
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned9
Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia9
Deterministic Sensitivity Analysis Under Ignorance9
Risk-Adjusted Performance Measures: A Comment on Elbasha9
Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses9
Incorporating Real Option Value in Valuing Innovation: A Way Forward9
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation9
Best Practices: A Collection of Systematic Critical Reviews of Modeling Approaches in Specific Disease Areas9
A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets9
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS9
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based 9
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions9
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling9
Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia9
Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review9
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges9
Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review8
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal8
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective8
Comment on: A Framework for the Fair Pricing of Medicines8
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations8
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review8
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies8
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group P8
Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis8
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE 8
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA8
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum8
A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus8
0.13548398017883